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Intragenic deletions of ALDH7A1 in
pyridoxine-dependent epilepsy caused by
Alu-Alu recombination
ABSTRACT
Objective: To investigate the role of intragenic deletions of ALDH7A1 in patients with clinical and
biochemical evidence of pyridoxine-dependent epilepsy but only a single identifiable mutation in
ALDH7A1.
Methods: We designed a custom oligonucleotide array with high-density probe coverage across
the ALDH7A1 gene. We performed array comparative genomic hybridization in 6 patients with
clinical and biochemical evidence of pyridoxine-dependent epilepsy but only a single detectable
mutation in ALDH7A1 by sequence analysis.
Results: We found partial deletions of ALDH7A1 in 5 of 6 patients. Breakpoint analysis reveals
that the deletions are likely a result of Alu-Alu recombination in all cases. The density of Alu
elements within introns of ALDH7A1 suggests susceptibility to recurrent rearrangement.
Conclusion: Patients with clinical pyridoxine-dependent epilepsy and a single identifiable muta-
tion in ALDH7A1 warrant further investigation for copy number changes involving the ALHD7A1
gene. Neurology® 2015;85:756–762
GLOSSARY
a-AASA 5 a-aminoadipic semialdehyde; CGH 5 comparative genomic hybridization; PDE 5 pyridoxine-dependent epilepsy.
First described in 1954, pyridoxine-dependent epilepsy (PDE) is a metabolic epileptic enceph-
alopathy characterized by pharmacoresistant seizures that typically come under control after
initial administration followed by supplementation of pyridoxine at pharmacologic doses.
The biochemical and genetic bases of this rare familial epilepsy were solved in 2006 when
mutations in ALDH7A1 resulting in dysfunction of the protein antiquitin were discovered.1
Metabolic changes consistent with PDE can be detected by measuring elevated levels of the
biomarker a-aminoadipic semialdehyde (a-AASA) in various body fluids.1,2 As elevations of
a-AASA are also present in patients with molybdenum cofactor deficiency and isolated sulfite
oxidase deficiency,3 genotyping of ALDH7A1 is required to confirm the diagnosis. In the vast
majority of published cases, homozygous or compound heterozygous mutations of both
ALDH7A1 alleles have been detected.
We investigated 6 patients with a clinical diagnosis of PDE and positive biomarkers in which
only a single, heterozygous mutation in ALDH7A1 could be identified by sequence analysis. We
designed a custom oligonucleotide array that included high-density probe coverage of the
ALDH7A1 gene to look for intragenic deletions or duplications that would have been missed
by conventional sequence analysis. Using this strategy, we found partial deletions of ALDH7A1
in 5 of 6 patients, each of which is likely the result of an Alu-Alu recombination event. Our
results suggest that in patients with clinical and biochemical evidence of PDE in the setting of a
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single sequence mutation in ALDH7A1, stud-
ies directed at identifying intragenic deletions
or duplications should be performed to iden-
tify the second mutation.
METHODS Standard protocol approvals, registrations,
and patient consents. Patient samples and clinical information
were collected after informed consent was obtained. This study
was approved by ethics boards at the University of Washington
and Great Ormond Street Hospital for Children, London, UK.
In 5 cases, we examined DNA from the proband; in one case,
we tested DNA from the father of a proband in whom a single,
maternally inherited ALDH7A1 mutation had been identified
(DNA for the proband was not available). Cases 1 and 1a (sibling)
were previously published4 as K3008-3 and K3008-4; cases 2–4
were published as cases F19, F8, and F16, respectively5; case 5 in
this study is the father of previously published6 case 17. Case 6
was also previously reported.7
Array comparative genomic hybridization. We performed
array comparative genomic hybridization (CGH) using a custom
oligonucleotide array that had 489 probes within the ALDH7A1
gene. All available probes in each exon as well as 5 kb upstream of
the promoter were used, resulting in an average of 4 probes per
exon. Average probe spacing in the introns was 1 kb; in addition,
probes were placed 1 per 1 kb across the 100 kb 39 and 59 of the
gene. We used standard PCR and Sanger sequencing to identify
precise deletion breakpoints when possible.
RESULTS We identified 6 patients with a clinical
and biochemical diagnosis of PDE described in
the literature for which only a single mutation in
ALDH7A1 had been identified (table 1). We were
able to test DNA from 5 of those patients and from
the obligate carrier father of the sixth patient. We
hypothesized that the second mutation in each case
could be an intragenic deletion or duplication involv-
ing the ADLH7A1 gene. We found a deletion encom-
passing at least one exon of the ALDH7A1 gene in 5
of 6 cases (83%; table 2, figure 1).
For 2 samples, we were able to perform additional
studies to determine precise deletion breakpoints.
Case 1 and his affected brother have a 2,366-bp dele-
tion encompassing the entire exon 7 (45 bp) as well
as ;1 kb of intronic sequence on either side of the
exon (figure 2). The resulting protein is predicted to
have an in-frame deletion of 15 amino acids. The
Table 1 ALDH7A1 mutations in the literature
Study
No. of
families
No. with both
mutations identified
No. with large
deletion mutation
No. with single
mutation identified
Mills et al.5 30 27 0 3a
Scharer et al.11 15 15 0 0
Bennett et al.4 15b 14 0 1a
Kanno et al.9 4c 4 1 (exon 17) 0
Plecko et al.6 16 14 1 (exon 7) 2d
Mills et al.1 8 8 0 0
Perez et al.8 12 12 1 (exons 12–18) 0
Kluger et al.7 1 0 0 1a
Total 100 94 3 7d
a These cases are included in the current study and found to have a deletion as the second
mutation.
b Three additional late-onset families with no mutations identified are not included in the
table.
cOne patient with normal pipecolic acid levels and no mutations identified is not included in
the table.
dOne of these patients was later found to have a silent V250V mutation.
Table 2 Genotype and phenotype information for patients with heterozygous ALDH7A1 deletions
Case
ALDH7A1
missense
ALDH7A1
deletion
Age at
seizure
onset Initial seizures EEG findings
Development and current
status a-AASA
1, Bennett
et al.4
c.1197G.T
(p.E399D)
Exon 7 3.5 wk Behavioral arrest,
eye aversion,
perioral cyanosis
Bilateral independent
onset of focal seizures,
temporal regions
Persistent focal seizures;
normal IQ; competitive
athlete; college graduate
Plasma AASA 5 3.4
mmol/L (normal ,0.3)
1a (sib),
Bennett
et al.4
c.1197G.T
(p.E399D)
Exon 7 9 mo Perioral cyanosis,
loss of body tone
Unk Normal IQ; competitive
athlete, attends college
Plasma AASA 5 3.8
mmol/L (normal ,0.3)
2, Mills
et al.5
c.523T.G
(p.W175G)
Exon 18 14 mo Clonic, myoclonic,
generalized tonic
3–4 c/s activity
postcentrally, irregular
fast spikes bilaterally
Normal IQ, some memory
problems
Urinary AASA 5 1.3
mmol/mol creatinine
(normal #1)
3, Mills
et al.5
c.1195G.C
(p.E399Q)
Exon 7 6 d Unk Unk Unk Urinary AASA 5 21
mmol/mol creatinine
(normal ,1)
4, Mills
et al.5
c.866C.T
(p.S289L)
Exons 14–17 5 d Clonic, generalized
tonic
L-sided epileptiform
discharges
Normal development at 18
mo
Urinary AASA 5 8
mmol/mol creatinine
(normal #2.5)
5, Plecko
et al.6
c.788G.A
(p.G263E)
Exons, 8–9 Unk Unk Unk Unk Unk
6, Kluger
et al.7
c.75insA (second
mutation not
found)
None
detected
10 d Prolonged tonic
clonic
Focal dysrhythmias
without epileptic
discharge; generalized
spikes
Normal IQ, attends college Urinary AASA 5 7.5
mmol/mol creatinine
(normal ,0.4)
Abbreviations: a-AASA 5 a-aminoadipic semialdehyde; Unk 5 unknown.
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deletion is inherited from the mother and the point
mutation (c.1197G.T) from the father. We
sequenced the genomic breakpoints of the deletion
and found that the deletion is the result of Alu-Alu
recombination between an AluY at the proximal
breakpoint and an AluSq2 at the distal breakpoint
that share 82% identity across 288 bp with an
11-bp stretch of identical sequence at the breakpoint.
For case 2, array studies identified a 70,283-bp
deletion encompassing the entire terminal exon 18
(55 bp) and ;1 kb of intronic sequence upstream
of the exon, ;50 kb of 39 UTR, and the last 9 exons
of the GRAMD3 gene (figure 3). We sequenced the
breakpoints of the deletion and, similar to case 1, each
breakpoint lies within an Alu element. This suggests
that the deletion is the result of Alu-Alu recombina-
tion between an AluSx element at both the proximal
and distal breakpoints that share 85% identity across
133 bp with an 18-bp stretch of identical sequence at
the breakpoint. The predicted effect of this deletion is
unclear, though it is not likely to result in a fusion
protein given that ALDH7A1 andGRAMD3 are tran-
scribed in opposite directions. There is no known
disease associated with GRAMD3 mutations, and
the phenotype of this patient is consistent with typical
PDE, so it is possible that the partial deletion of
GRAMD3 is benign. This is supported by the finding
of partial GRAMD3 deletions in the Database of
Genomic Variants (http://dgv.tcag.ca/).
Array studies also identified a minimum 1.7-kb
deletion encompassing the entire exon 7 (45 bp) in
case 3. This deletion appears to be similar to the dele-
tion in case 1 (figures 1 and 2). Case 4 carries a;6 kb
deletion encompassing exons 14–17, and the carrier
father in case 5 has a;10 kb deletion encompassing
exons 8 and 9 (figure 3). Though we did not have
adequate DNA to perform breakpoint sequencing,
we find that in each of these cases, the breakpoint
regions encompass a cluster of Alu elements (figure 3),
suggesting Alu-Alu recombination as a likely mecha-
nism generating each deletion. No deletions or
duplications involving ALDH7A1 were identified in
case 6. While the deletion in cases 1 and 3 is predicted
to cause an in-frame deletion of 15 amino acids, the
deletions in the other cases are not in-frame and likely
lead to premature truncation of the protein.
Figure 1 Intragenic deletions of ALDH7A1
(A) Deletions in 5 unrelated individuals with pyridoxine-dependent epilepsy and a single mutation identified by Sanger
sequencing. Each deletion involves at least one exon of the ALDH7A1 gene. (B) Expanded view of the deletion in case 2,
which extends proximally to the GRAMD3 gene and is only partially represented in A.
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We also performed array CGH for 3 individuals
(K-3003-3, K-3009-3, K-3018-3) with late-onset
pyridoxine-dependent seizures who had no mutations
in ALDH7A1 by sequence analysis.4 These individu-
als, whose biomarkers were less conclusive, did not
have any detectable deletions or duplications in the
ALDH7A1 gene. We have evaluated 138 other indi-
viduals who do not have PDE using the same array
(data not shown), and none has exhibited exon-
containing deletions or duplications of ALDH7A1.
Furthermore, there are no copy number variants within
the ALDH7A1 gene reported in the Database of
Genomic Variants (http://projects.tcag.ca/variation).
DISCUSSION Using a custom array, we identified
heterozygous intragenic deletions in the ALDH7A1
gene in 5 of 6 patients with PDE and positive bio-
markers who had only a single mutation identified by
conventional sequence analysis. The deletions range
in size from 1.7 to 70 kb and encompassed 1–4 exons.
In each case, the deletion breakpoints appear to lie
within Alu elements, suggesting that aberrant recom-
bination is the mechanism that generated the dele-
tions. Alu elements are a family of short (;300 bp)
interspersed repeat elements in the human genome
that are remnants of once-active transposable
elements. Although not identical in sequence, they
are highly related to each other, which can facilitate
aberrant recombination and subsequent deletion or
duplication, making them an important source of
mutation.
Deletions within the ALDH7A1 gene have been
reported in only 3 cases in the literature (table 1).
One individual was found to have a deletion of exon
7 (case 7, c.567_611del) by sequencing cDNA. In
another study, a patient with a deletion encompassing
exons 12–18 was identified by CGH, though the
precise genomic breakpoints were not evaluated in
Figure 2 Detailed analysis of deletions in cases 1 and 2 reveals Alu elements at the breakpoints
Deletion breakpoints in cases 1 (A) and 2 (B) were sequenced and found to lie within Alu elements. Approximate location of
breakpoints is indicated by red arrows. In A, array data for case 3 are shown, but only the breakpoints of case 1 were
sequenced.
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either case.6,8 A third case was reported to have a
deletion of exon 17 due to an Alu-Alu recombination
event in introns 16 and 17.9 Notably, 2 of 5 deletions
in our study encompass exon 7, suggesting that this
exon may be particularly susceptible to deletion. In
the 2 cases where we had sufficient DNA to sequence
the deletion breakpoints, we found that the break-
points lie within Alu elements. Furthermore, in the
remaining cases, array CGH data show that the
breakpoints are also predicted to be within a cluster
of Alu elements. The ALDH7A1 gene is relatively
Alu-rich, with 33% of the sequence made up of Alu
repeats, compared to the genome average of 10%.10
Of 100 families studied in the literature, both mu-
tations in ALDH7A1 had been found in 94 families,
and only a single mutation had been identified in 6
families1,4–6,8,9,11 (table 1). Here, we identify the sec-
ond mutation in 5 of the 6 unexplained families in
the literature. Specialized studies to detect genomic
rearrangements should be considered when only a
single mutation is identified. While we selected cus-
tom CGH, other methods that might be employed in
the clinical laboratory include quantitative PCR or
multiplex ligation-dependent probe amplification.
Notably, the deletions in 4 of our 5 cases are
;10 kb or less; therefore, detection by standard chro-
mosome microarray would depend on the resolution
of the array employed by the laboratory. cDNA
sequencing could be considered if cell lines are avail-
able. We were unable to identify a second mutation in
patient 6 in our study. It is possible that this patient
has a mutation in regulatory or intronic sequence
outside of the canonical splice site that would have
been missed by prior sequencing efforts. Additional
studies, such as whole-genome sequencing or RNA
studies, might help identify a second mutation,
though these studies were not possible due to lack
of material.
More than 60 ALDH7A1 sequence alterations
have been documented in affected individuals, but
Figure 3 Breakpoint regions of cases 3, 4, and 5 contain Alu elements
Deletion breakpoints in cases 3 (A), 4 (B), and 5 (C) are located within clusters of Alu elements. Deleted region in each case is
indicated by the solid red bar; the dotted bar indicates the breakpoint region as determined by the region between the last
deleted probe and the next probe with normal log2 ratio. In each case, the breakpoint region is within a cluster of Alu
elements.
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genotype–phenotype studies have failed to identify
any strong genotype–phenotype correlations.5,11,12
Patients with missense mutations that result in resid-
ual enzyme activity tend to have a milder phenotype
with better developmental outcome and response to
treatment.11 Nine mutations represent 61% of disease
alleles; the “common” p.E399Q (c.1195C.G) alter-
ation represents approximately 1/3 of the mutated
alleles and has been reported in both neonatal-onset
and late-onset cases.4 Indeed, in addition to the exon
7 deletion reported here, the 399 residue was also
mutated in case 1 and his brother (case 1b); however,
their mutation (p.E399D, c.1197G.T) is novel.
Both of these siblings have had favorable develop-
mental outcomes. Curiously, they have different
phenotypes, as the older boy presented with neonatal-
onset seizures (which are incompletely controlled even
with antiepileptic drugs) while the younger boy’s
seizures did not develop until 9 months of age. To
our knowledge, there are no other PDE families
reported where seizures presented in affected siblings
at such different ages. The mutations in case 3 are
similar to those in the siblings (p.E399Q and exon 7
deletion). Age at onset in this patient was 6 days.
The variable time of seizure onset in this family and
another patient with similar genotype supports the
suggestion that nongenetic factors may contribute to
the phenotypic spectrum of PDE.11 Genetic factors,
including different second mutations in ALDH7A1,
may also contribute. Case 2 did not present until 14
months of age, suggesting that one or both muta-
tions in this patient may have a mild effect. The
deletion in case 2 involves only the last exon of
ALDH7A1, while the second mutation is a missense
(W175G). One other patient with the W175G
mutation also had a late-onset phenotype.5 Overall,
the patients in our series with one point mutation
and one deletion mutation do not have markedly
different phenotypes vs patients with 2 point muta-
tions (table 2). While most patients in our series are
reported to have normal IQ, detailed testing results
were not available to determine whether any had
specific learning deficits.
Deletions involving exon sequence within the
ALDH7A1 gene account for the majority of muta-
tions in patients with PDE who have positive bio-
markers but only one documented mutation by
sequence analysis, and the density of Alu elements
within intronic regions may facilitate intragenic dele-
tions. These results also emphasize the clinical impor-
tance of assessing biomarkers in patients with a
suspected diagnosis, even when only a single genetic
mutation is found. Evaluation of exon copy number
using a custom array like the one described here or
another method should be implemented in the diag-
nostic laboratory for this purpose.
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